PT-217 is under clinical development by Phanes Therapeutics and currently in Phase II for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET). According to GlobalData, Phase II drugs for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PT-217’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PT-217 overview
PT-217 is under development for the treatment of small-cell lung cancer, large cell neuroendocrine cancer, neuroendocrine prostate cancer and gastroenteropancreatic neuroendocrine tumors (GEP-NET), neuroendocrine carcinoma. The drug candidate is a bi-specific monoclonal antibody acts by targeting cells expressing DLL3 and leukocyte surface antigen CD47. It is administered by intravenous route.
Phanes Therapeutics overview
Phanes Therapeutics is developing drugs for the treatment of immuno-oncology diseases. The company is headquartered in San Diego, California, the US.
For a complete picture of PT-217’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.